Matt Hewitt
Stock Analyst at Craig-Hallum
(2.62)
# 2,082
Out of 5,132 analysts
43
Total ratings
54.05%
Success rate
2.89%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $12.29 | +192.92% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.20 | +93.70% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.02 | +197.03% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $22.23 | +43.95% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $36.47 | +75.48% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $183.83 | -23.84% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.28 | +3,411.24% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $11.40 | +163.16% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $0.72 | +871.68% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $136.44 | +46.58% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.70 | +488.24% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $4.65 | +545.16% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.30 | +131,913.20% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $12.29
Upside: +192.92%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.20
Upside: +93.70%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.02
Upside: +197.03%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $22.23
Upside: +43.95%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $36.47
Upside: +75.48%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $183.83
Upside: -23.84%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.28
Upside: +3,411.24%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $11.40
Upside: +163.16%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $0.72
Upside: +871.68%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $136.44
Upside: +46.58%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $4.65
Upside: +545.16%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.30
Upside: +131,913.20%